ferrous gluconate has been researched along with methyldopa in 1 studies
| Studies (ferrous gluconate) | Trials (ferrous gluconate) | Recent Studies (post-2010) (ferrous gluconate) | Studies (methyldopa) | Trials (methyldopa) | Recent Studies (post-2010) (methyldopa) |
|---|---|---|---|---|---|
| 92 | 31 | 25 | 3,719 | 420 | 143 |
| Protein | Taxonomy | ferrous gluconate (IC50) | methyldopa (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 5.228 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.176 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, N; Paddock, V; Sundaram, R | 1 |
1 trial(s) available for ferrous gluconate and methyldopa
| Article | Year |
|---|---|
Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Drug Interactions; Female; Ferrous Compounds; Humans; Hypertension; Intestinal Absorption; Male; Methyldopa; Random Allocation | 1988 |